Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa, Open-label, Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of BP1001 (a Liposomal Grb2 Antisense Oligonucleotide) in Combination With Venetoclax Plus Decitabine in Patients With AML Who Are Ineligible for Intensive Induction Therapy

NCT02781883 is registered in ClinicalTrials.gov with Bio-Path Holdings, Inc. as lead sponsor.

NCT NCT02781883
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02781883 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa, Open-label, Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of BP1001 (a Liposomal Grb2 Antisense Oligonucleotide) in Combination With Venetoclax Plus Decitabine in Patients With AML Who Are Ineligible for Intensive Induction Therapy
Lead sponsor
Bio-Path Holdings, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
May 31, 2016
Completion date
December 31, 2028
Enrollment
108 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml)